🔴 Nuvation Bio is trading 4% down today after a wider-than-expected EPS loss despite strong IBTROZI sales

Nuvation Bio is trading at $6.12 (-4.00%) after its August 6, 2026, earnings showed strong IBTROZI sales but a wider-than-expected loss.

• Second-quarter revenue reached $31.7 million, including $23.2 million from IBTROZI, up 25% quarter over quarter
• Net loss was $0.18 per share and $62.8 million
• Management reaffirmed confidence in second-half 2026 revenue acceleration, though investors appear focused on the earnings-quality imbalance